Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-EXT open-label extension of odevixibat in children with biliary atresia
MOH_2022-08-23_011994Phase 3Completed
- Sponsor
- Albireo Pharma
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in biliary atresia, sponsored by Albireo Pharma. Primary endpoint: Long-term effect on native liver survival. Started Aug 2022; status: completed.
02
Drugs
odevixibat
03
Conditions
biliary atresia
Beyond the preview
Go deeper on MOH_2022-08-23_011994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-23_011994.